Abstract
Clinical impact of relative dose intensity of cabozantinib during the first 8 weeks and of subsequent dose reductions in patients with unresectable hepatocellular carcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have